Related Experiment Video
Updated: Jul 15, 2026
Novel Diagnostics in Revision Arthroplasty: Implant Sonication and Multiplex Polymerase Chain Reaction
Published on: December 3, 2017
High vs. low vancomycin therapeutic concentrations in periprosthetic joint infection: A retrospective cohort analysis
Jingdong Cheng1,2, Dehua Wang3, Yanqing Chen2
1Department of Pharmacy, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.
Objective:
Current guidelines recommend vancomycin concentrations of 10-20 μg/mL for most infections, with higher levels (15-20 μg/mL) suggested for severe cases. However, evidence supporting these recommendations in periprosthetic joint infection (PJI) is limited. This study aims to evaluate the impact of different vancomycin concentration ranges (10-15 vs. 15-20 μg/mL) on the safety and effectiveness in PJI population.
Methods:
This retrospective study included 37 patients with vancomycin Therapeutic Drug Monitoring due to periprosthetic joint infection. Patients were categorized into two groups according to vancomycin concentrations, low concentration group (10-15 μg/mL) and high concentration group (15-20 μg/mL). Patients were followed up for at least 2 years. The long term clinical outcomes, inflammatory markers, as well as adverse events were compared. A physiologically based pharmacokinetic model was established to compare vancomycin distribution in kidney and bone marrow between the two groups.
Results:
There were 23 (62.16%) patients classified as the HC group and 14 (37.84%) as the LC group. The average steady-state trough concentration (Css) in the HC group was 17.74 μg/mL, and in the LC group was 12.11 μg/mL. At the end of follow-up, two patients (5.40%) in the HC group had died, and one (2.7%) was readmitted for joint fusion due to recurrent infections, whereas no deaths or readmissions occurred in the LC group. However, no significant differences were identified. Similar improvements from baseline were observed across WOMAC, Harris, HSS, and SF-12 scores between the groups. The synovial white blood cell (WBC) count was significantly lower in the HC group compared to the LC group (5,481 vs. 7,106/μL, P = 0.009), with a more pronounced reduction from baseline noted. The PBPK model showed a greater increase in drug distribution to the bone marrow in the HC group (20.66 μg/mL vs. 14.34 μg/mL), with a smaller rise in the kidney (376.2 μg/mL vs. 327.7 μg/mL).
Conclusion:
Maintaining vancomycin concentrations of 15-20 μg/mL is associated with better infection control for PJI patients who present with higher synovial WBC account, without compromising patient safety, joint function, or long-term quality of life.
Insights
Higher vancomycin levels (15-20 μg/mL) improved infection control in periprosthetic joint infection (PJI) patients with elevated synovial white blood cell counts. This approach maintained patient safety and joint function, supporting its use in PJI management.
Area of Science:
- Infectious Diseases
- Orthopedic Surgery
- Pharmacology
Background:
- Current vancomycin guidelines lack specific evidence for periprosthetic joint infection (PJI).
- Recommended vancomycin concentrations (10-20 μg/mL) may not be optimized for PJI treatment.
- Limited data exists on the safety and efficacy of different vancomycin dosing strategies in PJI.
Purpose of the Study:
- To evaluate the impact of vancomycin concentration ranges (10-15 vs. 15-20 μg/mL) on PJI outcomes.
- To compare clinical effectiveness, inflammatory markers, and adverse events between vancomycin concentration groups.
- To assess vancomycin distribution in bone marrow and kidney using a pharmacokinetic model.
Main Methods:
- Retrospective study of 37 PJI patients undergoing vancomycin therapeutic drug monitoring.
- Patients divided into low (10-15 μg/mL) and high (15-20 μg/mL) concentration groups.
- Long-term follow-up (≥2 years) including clinical outcomes, inflammatory markers, adverse events, and PBPK modeling.
Main Results:
- Higher vancomycin concentration (15-20 μg/mL) group showed significantly lower synovial white blood cell (WBC) counts (P=0.009).
- Physiologically based pharmacokinetic (PBPK) model indicated greater vancomycin distribution to bone marrow in the high concentration group.
- No significant differences in mortality, readmissions, or functional scores (WOMAC, Harris, HSS, SF-12) were observed between groups.
Conclusions:
- Vancomycin concentrations of 15-20 μg/mL are associated with improved infection control in PJI patients with high synovial WBC counts.
- This higher concentration range did not compromise patient safety, joint function, or quality of life.
- Targeting higher vancomycin levels may be beneficial for managing PJI, particularly in cases with elevated inflammatory markers.
Related Concept Videos
01:26Factors Affecting the Risk of Infection
The integrity and count of the white blood cells help the body resist pathogens and fight infection. When impaired, it reduces the body's resistance to pathogens. The acidic pH levels of the gastrointestinal, genitourinary tracts, and skin create...
01:18Endocarditis III: Medical Management
01:30Urinary Tract Infection III: Diagnostic Studies and Interprofessional Care
01:28Acute Pyelonephritis II: Diagnostic Studies and Management
01:28Antimicrobial Effectiveness
01:25Clinical Significance of Antibiotic Resistance